When: $109.50 trigger (less than 1% above spot, within 2.83 ATR)

Then: Do not add — mathematically meaningless noise trigger

When: Waiting for $100-104 or Q3 confirmation

Then: Do not wait indefinitely — operationally fragile, low probability pullback given buyback support

HOLD - Do not add on breakout; maintain existing position with tightened stops at $102-104; wait for pullback to $100-104 zone or Q3 confirmation before adding

• MACD histogram collapsed from $1.10 to $0.10 in approximately 12 sessions, indicating near-complete momentum exhaustion rather than subtle deceleration
• RSI at 69 is not meaningfully lower—stock was at RSI 74 on July 29th and the only reason it's at 69 is momentum has cooled, signaling the upside move has lost steam
• 22% vertical move in four weeks with compressing momentum creates asymmetric risk toward pullback rather than breakout
• 17.9x forward P/E at $108.62 using $6.06 consensus EPS offers no margin of safety given Q1's 48% YoY EPS collapse
• $34 billion debt load is not yet absorbed into run rate—Q1 2026 showed first full quarter with elevated debt and 12% operating margin compression
• $3 billion annual deleveraging assumes $7.2B FCF with no working capital deterioration, margin pressure, or integration cash drag
• China VBP being a 'tired narrative' makes it persistent rather than resolved—EPD segment most exposed to structural pricing reform
• Six conditions needed for bull case to work: Exact Sciences synergy targets, margin recovery to 17-18%, China VBP stability, smooth deleveraging, macro stability, and integration success
• Breakout entry at $109.50 with $95 stop creates $14.50 downside per share against $30.50 upside target—risk-reward shifts against adding after 22% rally
• Q3 October print serves as critical validation or invalidation point for the integration and recovery thesis

→ vs aggressive: MACD histogram interpretation shows confirmation bias—framing compression as 'digestion' ignores that $1.10 to $0.10 in 12 sessions is momentum exhaustion, not healthy consolidation

→ vs aggressive: RSI 69 framing as 'not overbought' ignores that RSI was 74 on July 29th—indicator shows upside momentum has cooled, not that more upside remains

→ vs aggressive: EPS stress-testing discipline is correct even if the $5.00 estimate is wrong—17.9x forward P/E offers no margin of safety for a name that just showed 48% EPS collapse

→ vs aggressive: 'Good enough' requires six simultaneous outcomes (synergy targets, margin recovery, China stability, deleveraging, macro stability, integration success)—that is not low-risk, that is multi-variable dependency

→ vs aggressive: Macro being 'neutral to mildly supportive' for defensives ignores the negative translation impact of stronger dollar on international revenue and that 'no Fed cuts' doesn't actively support defensives

→ vs aggressive: Tight stop at $95 is too generous for a defensive name that has already bounced 22%—12.5% drawdown tolerance is inappropriate given momentum showing fatigue

→ vs aggressive: Risk-reward math reverses when probability-weighted—pullback to $100-104 before new highs is substantially more likely than 50% chance of immediate breakout

HOLD

• MACD momentum has paused — next move will be directionally significant, not a green or red light
• RSI at 69 is a yellow light confirming elevated but non-accelerating buying pressure
• Consensus forward EPS is 6.06 (not 5.00), putting forward P/E at 17.9x (not 21.7x)
• Q1 2026 showed 48% YoY EPS collapse and 12% operating margin — cannot be dismissed until Q2 margins reported
• Exact Sciences integration is the dominant variable to watch at next earnings print
• Macro setup is neutral to mildly positive, not screaming defensive healthcare — recession odds at 8%, Fed has priced out cuts
• Net debt/EBITDA of 2.3x is manageable and self-resolves over 12-24 months through FCF
• China VBP is a structural headwind being navigated successfully, but Q1 margin compression raises questions
• Breakout trigger at 109.50 is noise — less than 1% from current 108.62 with ATR of 2.83
• Stop at 102-104 may be too tight given ATR of 2.83 — routine volatility could trigger stop-out
• Preferred add trigger: confirmed breakout above 114 (Bollinger upper band) with volume expansion
• Alternative add: pullback to 102-104 holding 2-3 sessions with MACD histogram turning up
• Catastrophic stop maintained at 95 (12.5% below current 108.62)
• Secondary rule: close below 102 on volume triggers 1/3 position reduction
• Add quarter-size increment rather than half-size given conflicted signals

→ vs aggressive: 109.50 breakout trigger is noise — less than 1% from current 108.62, will be hit on any mildly bullish day regardless of underlying strength

→ vs aggressive: Macro 'screaming defensive healthcare' is overstated — recession odds at 8%, Fed has priced out cuts, strong dollar hurts international translation

→ vs aggressive: Dismissive 'tired narrative' framing on China VBP risks getting blindsided when stale narratives become urgent

→ vs aggressive: 'Good enough' framing on flawless execution is rhetorically clever but intellectually lazy

→ vs aggressive: Framework requires conviction in face of conflicting signals and leaves no room for position to be wrong

→ vs conservative: 102-104 stop is too tight given ATR of 2.83 — routine 4-6 dollar pullback would trigger stop on normal volatility

→ vs conservative: 'Six things need to go right' sets impossibly high bar when realistically 1-2 variables matter most

→ vs conservative: Using 5.00 forward EPS to calculate 21.7x P/E is cherry-picked — consensus is 6.06 for 17.9x

→ vs conservative: Overstating strong dollar headwind on EPD — local-currency contracts have natural offsets

→ vs conservative: Framework requires near-perfection in entry timing and ignores real chance ABT runs away to upside if Q3 validates thesis